Synthon (Netherlands)

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji, Carla M.L. van Herpen, Cristina Saura et al. · The Lancet Oncology · 2019 · 549 citations · Full text

Breast Oncology, Her2-expressing Breast Cancer, Medicine +9

“Cascade‐Release Dendrimers” Liberate All End Groups upon a Single Triggering Event in the Dendritic Core

Franciscus M. H. de Groot, C. Albrecht, Ralph Koekkoek et al. · Angewandte Chemie International Edition · 2003 · 237 citations · Full text

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

Ronald C. Elgersma, Ruud G. E. Coumans, Tijl Huijbregts et al. · Molecular Pharmaceutics · 2015 · 214 citations · Full text

Molecular Biology, Duocarmycin 3B, Pharmaceutical Chemistry +16

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

Miranda M.C. van der Lee, Patrick G. Groothuis, Ruud Ubink et al. · Molecular Cancer Therapeutics · 2015 · 208 citations

Breast Oncology, Immunology, Pathology +20

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

Wim H.A. Dokter, Ruud Ubink, Miranda van der Lee et al. · Molecular Cancer Therapeutics · 2014 · 156 citations · Full text

Drug Target, Immunology, Molecular Biology +18